These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7744164)

  • 21. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical and intradermal Bacillus Calmette-Guérin application. A phase I study to the toxicity of a Dutch Bacillus Calmette-Guérin preparation in patients with superficial bladder cancer.
    Schreinemachers LM; van der Meijden AP; Wagenaar J; Steerenberg PA; Feitz WF; Groothuis DG; Tiesjema RH; de Jong WH; Debruyne FM; Ruitenberg EJ
    Eur Urol; 1988; 14(1):15-21. PubMed ID: 2963745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
    Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
    J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.
    D'Ancona CA; Netto Júnior NR; Claro JA; Ikari O
    J Urol; 1991 Mar; 145(3):498-501. PubMed ID: 1997698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Huang Z; Liu H; Wang Y; Zhang C; Xu T
    Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycobacterial sepsis following intravesical instillation of bacillus Calmette-Guérin.
    Garyfallou GT
    Acad Emerg Med; 1996 Feb; 3(2):157-60. PubMed ID: 8808378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
    Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
    Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ
    J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
    Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G
    Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCG in the treatment of superficial cancer of the bladder: a review.
    Friberg S
    Med Oncol Tumor Pharmacother; 1993; 10(1-2):31-6. PubMed ID: 8258992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy with bacille Calmette-Guérin in patients with superficial transitional cell carcinoma of the bladder associated with bilharziasis.
    Wishahi MM; Ismail IM; el-Sherbini M
    Br J Urol; 1994 Jun; 73(6):649-54. PubMed ID: 8032832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder tumors: effect of intravesical BCG on papillary tumors].
    Hagiwara M; Asano T; Iigaya T; Tsukamoto T; Nishida K
    Nihon Hinyokika Gakkai Zasshi; 1986 Oct; 77(10):1623-30. PubMed ID: 3820900
    [No Abstract]   [Full Text] [Related]  

  • 38. Nursing aspects of bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
    LeBouton J
    Urol Nurs; 1990 Dec; 10(4):9-14. PubMed ID: 2274796
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications.
    Suzuki S; Shinohara N; Harabayashi T; Taniguchi A; Haga K; Sato S; Sakamoto K; Koyanagi T
    Int J Clin Oncol; 2002 Oct; 7(5):289-93. PubMed ID: 12402062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.